Radiotracers suitable for positron emission tomography studies often serve as preclinical tools for in vivo receptor occupancy. The serotonin 1B receptor (5-HT 1B ) subtype is a pharmacological target used to discover treatments for various psychiatric and neurological disorders. In psychiatry, 5-HT 1B antagonists may provide novel therapeutics for depression and anxiety. We report on the in vitro and in vivo evaluation of tritiated 5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylicacid (4-morpholin-4-yl-phenyl)-amide ([N-methyl- (Hoyer et al., 2002) . The serotonin 1B receptor (5-HT 1B ) subtype has been implicated in normal physiological functions and behavior and in neurological and psychiatric disorders, such as diseases of locomotion, migraine, drug abuse, aggressive behavior, anxiety, and depression [Moret and Briley, 2000; Svenningsson et al., 2006; for review, see Sari (2004)]. 5-HT 1B receptors modulate synaptic release of sero-M.D., M.E.Po., Q.J., and G.H. contributed equally to this work. Article, publication date, and citation information can be found at
H 3 ]AZ10419369), a potent 5-HT 1B radiotracer. [N-methyl-3 H 3 ]-AZ10419369 showed saturable single-site high-affinity in vitro binding (guinea pig, K d ϭ 0.38 and human, K d ϭ 0.37) to guinea pig or human 5-HT 1B receptors in recombinant membranes and high-affinity (K d ϭ 1.9 nM) saturable (B max ϭ 0.099 pmol/mg protein) binding in membranes from guinea pig striatum. When [N-methyl-3 H 3 ]AZ10419369 was administered to guinea pigs by intravenous bolus, the measured radioactivity was up to 5-fold higher in brain areas containing the 5-HT 1B receptor (striatum/globus pallidus, midbrain, hypothalamus, and frontal cortex) compared with the cerebellum, the nonspecific binding region. Specific uptake peaked 30 min after injection with slow dissociation from target regions, as suggested by the in vitro binding kinetic profile. Pretreatment with 6-fluoro-8-(4-methylpiperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-propionyl-piperazin-1-yl)-phenyl]-amide (AZD1134) and 2-aminotetralin (AR-A000002), 5-HT 1B -selective ligands, inhibited [N-methyl-3 H 3 ]AZ10419369-specific binding in a dose-dependent manner. In the guinea pig striatum, AZD1134 (ED 50 ϭ 0.017 mg/kg) occupies a greater percentage of the 5-HT 1B receptors at a lower administered dose than AR-A000002 (ED 50 ϭ 2.5 mg/kg). In vivo receptor occupancy is an essential component to build binding-efficacy-exposure relationships and compare novel compound pharmacology.
[N-methyl- 3 H 3 ]AZ10419369 is a useful preclinical tool for investigating 5-HT 1B receptor occupancy for novel compounds targeting this receptor.
5-Hydroxytryptamine (5-HT or serotonin) is a major neurotransmitter in the central and peripheral nervous systems, The action of 5-HT is mediated via six classes of G proteincoupled receptors (5-HT 1 , 5-HT 2 , 5-HT 4 , 5-HT 5 , 5-HT 6 , and 5-HT 7 ) that are further divided in total to at least 14 subtypes (Westkaemper and Roth, 2006 ) and a family of ligandgated 5-HT 3 ion channels further divided into three subtypes. The 5-HT 1 class of serotonergic receptor contains five subtypes (5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , and 5-HT 1F ) that are preferentially coupled to G i/o to inhibit cAMP formation (Hoyer et al., 2002) . The serotonin 1B receptor (5-HT 1B ) subtype has been implicated in normal physiological functions and behavior and in neurological and psychiatric disorders, such as diseases of locomotion, migraine, drug abuse, aggressive behavior, anxiety, and depression [Moret and Briley, 2000; Svenningsson et al., 2006 ; for review, see Sari (2004) ]. 5-HT 1B receptors modulate synaptic release of sero-tonin (Hoyer et al., 2002) acting as autoreceptors on serotoninergic terminals or as heteroreceptors on non-serotonergic neurons (Engel et al., 1986; Sari et al., 1999; Roberts et al., 2001; Sari, 2004) . Blocking 5-HT 1B autoreceptors with a selective ligand increases extracellular levels of 5-HT and has an additive effect on 5-HT increase when combined with selective serotonin reuptake inhibitors, suggesting the antidepressive potential of a 5-HT 1B drug (Matzen et al., 2000; Smagin et al., 2003) . Indeed, drugs targeting 5-HT 1B receptors have shown efficacy in animal models of depression and anxiety (Hudzik et al., 2003a,b; Dawson et al., 2006) . In humans, selective serotonin reuptake inhibitors usually have up to 4 weeks of delayed antidepressive effect attributed to gradual down-regulation and slow desensitization of 5-HT 1B autoreceptors. It has been suggested that targeting the 5-HT 1B receptor, as adjunct therapy to selective serotonin reuptake inhibitors, may shorten the delay in onset to antidepressant efficacy by direct autoreceptor blockage (Briley and Moret, 1993; Sari, 2004) .
Selective 5-HT 1B radiotracers are of paramount importance to the development of 5-HT 1B drugs to allow measurement of in vivo occupancy in small animals and for positron emission tomography (PET) ligands in monkey and human brain. In general, radiotracers that provide tools for the investigation of in vivo ligand binding require high affinity and selectivity at the target receptor are not substrates for efflux pumps and have moderate lipophilicity to improve brain penetration and reduce nonspecific binding (Passchier et al., 2002) . In vitro binding studies using cloned human 5-HT 1B receptors found high-affinity compounds selective for the 5-HT 1B receptor (Doménech et al., 1997; Huang et al., 2005 ). Autoradiography using [
3 H]GR125743 (incubated with 300 nM ketanserin to block 5-HT 1D binding) in human brain sections shows 5-HT 1B receptors in the basal ganglion, substantia nigra, and neocortex corresponding to 5-HT 1B protein expression (Varnä s et al., 2001 (Varnä s et al., , 2005 . The high degree of homology between the 5-HT 1B receptor in the guinea pig brain and the human 5-HT 1B receptor makes the guinea pig a suitable animal model for translational studies at the 5-HT 1B receptor (Zgombick et al., 1997) .
Until recently Pierson et al., 2007 Pierson et al., , 2008 , bioavailable 5-HT 1B receptor radiotracers for analyzing in vivo occupancy during preclinical development and PET imaging have been limited. We developed AZ10419369, a compound with high affinity for the 5-HT 1B receptor and physical-chemical properties suitable for an in vivo radioligand. Here, we describe the in vitro and in vivo pharmacological properties of tritiated AZ10419369 and show this radioligand as a preclinical tool for comparing novel 5-HT 1B compounds using receptor occupancy.
Materials and Methods
Adult Dunkin-Hartley male guinea pigs (180 -260 g) were purchased from Charles River Laboratories (Wilmington, MA (Ahlgren et al., 2004) and for AZD1134 (Horchler et al., 2007) 
Preparation of [N-methyl-3 H 3 ]AZ10419369
[N-methyl-3 H 3 ]AZ10419369 ( Fig. 1) was synthesized in the radiochemistry laboratory at AstraZeneca Pharmaceuticals. A solution of 1.6 mg (3.57 mol) of AZ12334550 in 400 l of dimethylformamide (DMF) was added to a solution of 170 mCi (85 Ci/mmol, 2.0 mol) of 3 H 3 CI in 100 l of DMF, and the sealed reaction mixture was heated at 110°C for 50 min. The reaction was cooled to 0°C, and 5 l (29 mol) of diisopropylethylamine and 3 mg (13.7 mol) of di-tert-butyl dicarbonate were added. The solution was stirred at 110°C for 30 min and cooled to 0°C, and a second aliquot of 5 l (29 mol) of diisopropylethylamine and 3 mg (13.7 mol) of di-tert-butyl dicarbonate was added; the resulting mixture was stirred at 110°C for 30 min. The reaction was concentrated to near dryness and was taken up in 600 l of EtOH to give 140 mCi. A portion (113 mCi) was purified by semipreparative high-performance liquid chromatography (10 ϫ 250-mm Phenomenex Luna C-18(2) column, 20 -60% MeCN/0.1% trifluoroacetic acid for 10 min, 3 ml/min, R T ϭ 8.1 min) to give 36.3 mCi (99.1% radiochemical purity determined as described above on a 4.6 ϫ 150-mm column, 80 Ci/mmol determined by LC/MS).
Human 5-HT 1B Receptor Binding Assay
Frozen membrane preparations of stably transfected CHO cells expressing human 5-HT 1B receptors (10 mg/ml) were rapidly thawed, briefly vortexed, and diluted in assay buffer (AB; pH 7.4) containing 50 mM Tris-HCl, 4 mM MgCl 2 , 4 mM CaCl 2 , and 1 mM EDTA. Membranes were resuspended in AB at 125 g/ml and dispensed at 80 l/well for a final concentration of 10 g/well. In saturation binding studies, [N-methyl-3 H 3 ]AZ10419369 (0.3-12 nM diluted in AB) was incubated with membranes alone (1-h incubation at RT) or in combination with AZD1134 (3.2 M) to define nonspecific binding. For concentration-response studies, 11 serial dilutions (10 M to 170 pM, final concentration in dimethyl sulfoxide) of drug were added to the radioligand and membrane mixture. Final assay volumes per well were 2 l of compound/nonspecific, 80 l of membranes, 20 l of [
N-methyl-3 H 3 ]AZ10419369 Binding to 5-HT 1B Receptors
[N-methyl-3 H 3 ]AZ10419369 (0.27 nM final concentration), and 100 l of AB. The assay plates were incubated for 90 min at RT and then filtered through Beckman GF/B filters (soaked Ͼ2 h in 0.6% polyethylenimine) using a Packard Filtermate 196 (PerkinElmer Life and Analytical Sciences). Filters were washed two times with 1 ml of ice-cold wash buffer (5 mM Tris-HCl, pH 7.4) and dried; 40 l of Microscint20 (PerkinElmer Life and Analytical Sciences) was added to each well, and the plates were counted on a Packard TopCount (PerkinElmer Life and Analytical Sciences).
Guinea Pig 5-HT 1B Receptor Binding Assay
Membranes were derived from HEK293F cells transiently transfected with the guinea pig 5-HT 1B receptor. Assay buffer, radioligand, filter plate procedure, and counting methods were unchanged from the human receptor binding assay. [N-methyl-3 H 3 ]AZ10419369 was used at 0.001 to 3.2 nM in the saturation binding experiment and at 0.35 to 0.5 nM in the competition binding studies (1 h incubation at RT). Methiothepin (10 M) was used to define nonspecific binding.
Guinea Pig and Monkey Membrane Preparation
Guinea pig membranes were derived from cortex, striatum/globus pallidus, and substantia nigra. Monkey membranes were derived from the cortex. Guinea pig or monkey brain tissue was homogenized in 20 mM Tris, pH 7.4, with protease inhibitors and centrifuged at 1000g for 5 min. The pellet was discarded, and the supernatant was centrifuged at 100,000g for 30 min. Pellet was resuspended in 20 mM Tris buffer, pH 7.4, and membrane protein concentration was measured by using a standard protein determination kit.
Guinea Pig and Monkey Membrane 5-HT 1B Receptor Binding Assay
Assay buffer, radioligand, filter plate procedure, and counting methods for the native tissue receptor assays were as described above for the recombinant receptor. In saturation binding assays, [N-methyl-3 H 3 ]AZ10419369 (0.14 -10 nM) was incubated (1 h at RT) alone or in competition with GR127935 (10 M) to define nonspecific binding. Native tissue membranes were used at a final concentration of 100 g/well in the binding assays.
[N-methyl-3 H 3 ]AZ10419369 in Vivo Binding
All guinea pigs were anesthetized with isoflurane. A 2-3 French catheter was inserted into the jugular vein and terminated at the right atrium. The exterior end of the cannula was fed subcutaneously, anchored to the skin dorsal to the shoulder blades and flushed with 0.9% saline with 100 units/ml heparin to test patency. The jugular cannula was inserted 1 to 2 days before intravenous injection of the radioligand.
To establish regional uptake and dose, [N-methyl-3 H 3 ]-AZ10419369 was administered at a volume of 1.0 ml/guinea pig by intravenous bolus to freely moving animals via the jugular cannula 15 min before euthanasia. Dosing solutions were prepared from [N-methyl-3 H 3 ]AZ10419369 stock (specific activity, 80 Ci/mmol) diluted to 2. 5, 5.0, 10.0, 15.0, 25.0, or 50 .0 Ci/ml with 0.9% saline. To establish the time course for in vivo binding, [N-methyl-3 H 3 ]-AZ10419369 (15 Ci/ml per guinea pig) was administered as an intravenous bolus and guinea pigs were euthanized 5, 15, 30, 60, or 90 min after radioligand injection. The brain was placed on a chilled plate for free-hand dissection into brain regions. Brain regions included the hypothalamus (HT), frontal cortex (FC), striatum/globus pallidus (STR), and cerebellum (CRB). Each tissue region was frozen, weighed, and transferred to scintillation vials containing tissue solubilizer, Soluene 350. Tissue was solubilized overnight, Ultima-Gold scintillation fluid was added, and total radioactivity was measured with a Tri-Carb scintillation counter (PerkinElmer Life and Analytical Sciences). Trunk blood samples were processed for scintillation count of radioactivity in the plasma. [N-methyl-3 H 3 ]AZ10419369 (15 Ci/ml i.v. per guinea pig) was administered alone or 30 min after pretreatment with AR-A000002 (100 mg/kg s.c.) or AZD1134 (10 mg/kg s.c.). Guinea pigs were euthanized 30 min after radiotracer administration; the whole brain was removed and rapidly frozen for cryosectioning. Sagittal sections (20 m thick) were thaw-mounted onto microscopy slides and dried. For regional localization of radioactivity, slides were exposed to a Fuji Imaging Plate for 5 days and processed by using the FujiFilm PhosphorImager, BAS5000 (FUJIFILM, Life Sciences, Stamford, CT). 
In Vivo Receptor Occupancy

Data Analysis and Statistics
In Vitro Binding. Data were analyzed by calculating percentage of control [average of (total sample binding Ϫ plate NSB)/(plate total Ϫ plate NSB) ϫ 100%], IC 50 , and K i using the Kenakin correction for ligand depletion in an XLfit template:
. L T and R T are the total concentrations of the ligand and receptor, respectively (in nanomoles).
In Vivo Occupancy. Radioactivity count (cpm), scintillation counter efficiency, and brain region weight were used to calculate femtomoles per milligram of tissue. Specific binding (fmol/mg tissue) was calculated from total binding for each brain region (fmol/mg tissue) by subtracting the (fmol/mg) values for the cerebellum (region of nonspecific receptor binding). Between-treatment-group comparisons were determined by using a one-way analysis of variance (ANOVA) with a Tukey post hoc test (SigmaStat; SPSS Inc., Chicago, IL). Percentage of receptor occupancy for the unlabeled compounds was calculated from specific binding values for each brain region, with occupancy of the vehicle set at zero. Sigmoidal percentage receptor occupancy curves were fit, and nonlinear regression analysis was used to calculate the ED 50 values by using Prism (GraphPad Software Inc., San Diego CA).
Results
Properties and Selectivity of AZ10419369. AZ10419369 has a molecular weight of 462.55, LogD of 2.5 at pH 7.4, a lipophilicity value suggesting low nonspecific binding, and an efflux ratio of 1.2, indicating good brain penetration. In a [ 35 S]GTP␥S functional assay, using CHO cell membranes expressing the recombinant human 5-HT 1B receptor, AZ10419369 profiles as a partial agonist in both the agonist and antagonist assay formats. AZ10419369 is able to inhibit agonist-induced 344 hypothermia in the guinea pig, but the data would not rule out partial agonist activity in vivo. AZ10419369 selectivity was tested at 1 M using radioligand in vitro binding assays for 169 targets in the SpectrumScreen Assay (MDS Pharma Services). Only seven targets showed a greater than 50% inhibition at 1 M. Compared with inhibition measured for the 5-HT 1B receptor, AZ10419369 showed 772-, 105-, 47-, 75-, 180-, 567-, and 279-fold selectivity for rat adrenergic receptor ␣1b, human histamine receptor H1, and human serotoninergic receptors 5-HT 1D , 5-HT 1A , 5-HT 2B , 5-HT 2C , and 5-HT 6 , respectively.
In (K d ϭ 3.85 nM) , whereas the highest affinity was seen in guinea pig striatum and substantia nigra (K d ϭ 1.9 and 1.5 nM, respectively). The receptor density was similar across brain regions. The receptor density in the guinea pig cortex (B max ϭ 0.349 pmol/mg protein) was ϳ2-fold more than that in the monkey cortex (B max ϭ 0.131 pmol/mg protein). The receptor density in the guinea pig striatum (B max ϭ 0.099 pmol/mg protein) and substantia nigra (B max ϭ 0.115 pmol/mg protein) is comparable. These differences are acceptable and within typical assay variability.
Binding kinetics of [N-methyl-3 H 3 ]AZ10419369 were determined by using transfected cell membranes expressing human or guinea pig 5-HT 1B receptors (Fig. 3). [N-methyl-3 H 3 ]AZ10419369 displays association kinetics for human and guinea pig 5-HT 1B receptors that is relatively rapid and typical for small molecules, whereas the dissociation rate is relatively slow. The in vitro association kinetics of [N-methyl-3 H 3 ]AZ10419369 to the human 5-HT 1B receptor is approximately t 1 ⁄2 of association of 5.6 min; k obs of association ϭ 0.124/min. This is comparable with the rapid association of the [N-methyl-3 H 3 ] AZ10419369 to the guinea pig 5-HT 1B receptor is rapid (approximate t 1/2 of association of 2.3 min; k obs of association ϭ 0.303/min) and the dissociation, by the addition of 5 M AZD1134, was very slow (t 1/2 of dissociation ϭ 107 min; k ϭ 0.006/min), with approximately 30% of the counts remaining bound after 3 h.
[N-methyl-3 H 3 ]AZ10419369 5-HT 1B selectivity and pharmacology were evaluated in transfected cell membranes containing the human and guinea pig 5-HT 1B receptors ( Table  2 ). The slow dissociation rate of [N-methyl-3 H 3 ]AZ10419369 does not allow for the measurement of true equilibrium binding in the time frame of the experiment, so the binding results are expressed as IC 50 values rather than K i values. Although the dissociation rate of [N-methyl-3 H 3 ]AZ10419369 is slow, a relative potency can be determined for the compounds, allowing a reasonable comparison ranking. The IC 50 value for AZ10419369 using [ 3 H]GR125743 was more potent at the guinea pig receptor than at the human receptor. IC 50 values for AZD1134 and AR-A000002 (selective 5-HT 1B receptor ligands) and ]AZ10419369 were comparable with the IC 50 values using [ 3 H]GR125743 for both human and guinea pig 5-HT 1B receptors. These (Fig. 4) . Regional uptake of [N-methyl-3 H 3 ]AZ10419369 was consistent with the gradient of regional distribution of 5-HT 1B receptors: highest in regions containing high amounts of the receptor, such as striatum/globus pallidus, and hypothalamus; and moderate, such as frontal cortex. [N-methyl-3 H 3 ]AZ10419369 accumulation was dose-dependent. Peak uptake and saturation in The time course study showed that [N-methyl-3 H 3 ]-AZ10419369 entered the brain rapidly (Fig. 5) . The uptake and distribution was similar to the dose-response data with [N-methyl-3 H 3 ]AZ10419369 (15 Ci/ml per guinea pig) uptake in the hypothalamus Ͼ striatum/globus pallidus Ͼ frontal cortex Ͼ cerebellum. The distribution of radioactivity peaked by 30 min in all target regions. [N-methyl-3 H 3 ]-AZ10419369 accumulation was not significantly different at 30, 60, and 90 min after intravenous injection, indicating that the binding in vivo had reached equilibrium. Radioactivity measured in the plasma from the terminal blood sample showed a dose-and time-dependent exposure of [N-methyl-3 H 3 ]AZ10419369, with 1596.1 Ϯ 86 dpm (mean Ϯ S.E.M.) measured at 30 min after administration of the 15 Ci/ml dose.
The pharmacological selectivity of [N-methyl-3 H 3 ]-AZ10419369 was also demonstrated after pretreatment with a high dose of AR-A00002 (100 mg/kg s.c.) 30 min after radiotracer administration (Fig. 6) [N-methyl-3 H 3 ]AZ10419369 in vivo accumulation, regional distribution, and pharmacological selectivity were also demonstrated by using autoradiography (Fig. 7) [N-methyl-3 H 3 ]AZ10419369 uptake was found in regions of the brain with high 5-HT 1B receptor density, including the striatum, globus pallidus, hypothalamus, and midbrain (inferior colliculus, substantia nigra). Regions with moderate 5-HT 1B receptor density or differences in subregion density include the cerebral cortex and hippocampus. In the cerebellum, the accumulation of [N-methyl-3 H 3 ]AZ10419369 was comparable with the background. AR-A00002 (100 mg/kg s.c.) and AZD1134 (10 mg/kg s.c.) pretreatment inhibited [N-methyl-3 H 3 ]AZ10419369 binding in regions of the brain containing the 5-HT 1B receptor (Fig. 6 , B and C, respectively). (Pierson et al., 2007) add further support for the translational value of this radioligand in drug discovery.
